Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

The primary objective of this trial is to collect, evaluate, and report observational data
about the clinical use of Xeomin® in a "real world" setting to determine which muscles are
injected, the dose used, and how doctors administer the injection.

The secondary objectives of this trial are: To collect and evaluate information about the
efficacy of Xeomin®. To collect and evaluate information about the effect of Xeomin® on work
productivity and quality of life. To monitor for any serious side effects and non-serious
related side effects of Xeomin®

Inclusion Criteria:

- Subjects 18 years of age or older.

- The physician must have chosen to treat the patient with Xeomin®
(incobotulinumtoxinA) prior to and independent of enrollment in this study.

- Subjects who are eligible to be treated with a botulinum toxin for cervical dystonia
or blepharospasm based upon the physicians' clinical experience. There are no
restrictive subject entry criteria.

- Subjects who are able to read, speak and understand English.

Exclusion Criteria:

- Subjects who are enrolled in any clinical trial (currently or within the past 3
months) in which treatments are imposed by a protocol are not eligible for this
trial.

- Any subject for whom botulinum toxin treatment would be contraindicated; see Xeomin®
Prescribing Information for further details.